Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Hezode

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Journal of Hepatology|March 10, 2016
Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trialZobair M Younossi, Maria Stepanova, Jordan Feld, et al.
Journal of Hepatology|April 10, 2014
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE studyZobair M Younossi, Maria Stepanova, Stefan Zeuzem, et al.
Hepatology (Baltimore, Md.)|June 27, 2002
Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replicationMagali Bouvier-Alias, Keyur Patel, Harel Dahari, et al.
Chest|July 12, 2016
Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial HypertensionLaurent Savale, Marie-Camille Chaumais, David Montani, et al.
Hepatology (Baltimore, Md.)|January 30, 2016
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)Vincent Leroy, Peter Angus, Jean-Pierre Bronowicki, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 2, 2018
Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia VasculitisPatrice Cacoub, Si Nafa Si Ahmed, Yasmina Ferfar, et al.
Gastroenterology|March 15, 2017
Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia VasculitisDavid Saadoun, Stanislas Pol, Yasmina Ferfar, et al.
Journal of Hepatology|January 18, 2015
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4Christophe Moreno, Christophe Hezode, Patrick Marcellin, et al.
Annals of the Rheumatic Diseases|November 15, 2015
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC studyDavid Saadoun, Vincent Thibault, Si Nafa Si Ahmed, et al.
Journal of Hepatology|December 10, 2017
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studiesChristophe Hezode, Nancy Reau, Evguenia S Svarovskaia, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Journal of Hepatology|March 10, 2016
Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trialZobair M Younossi, Maria Stepanova, Jordan Feld, et al.
Journal of Hepatology|April 10, 2014
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE studyZobair M Younossi, Maria Stepanova, Stefan Zeuzem, et al.
Hepatology (Baltimore, Md.)|June 27, 2002
Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replicationMagali Bouvier-Alias, Keyur Patel, Harel Dahari, et al.
Chest|July 12, 2016
Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial HypertensionLaurent Savale, Marie-Camille Chaumais, David Montani, et al.
Hepatology (Baltimore, Md.)|January 30, 2016
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)Vincent Leroy, Peter Angus, Jean-Pierre Bronowicki, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 2, 2018
Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia VasculitisPatrice Cacoub, Si Nafa Si Ahmed, Yasmina Ferfar, et al.
Gastroenterology|March 15, 2017
Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia VasculitisDavid Saadoun, Stanislas Pol, Yasmina Ferfar, et al.
Journal of Hepatology|January 18, 2015
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4Christophe Moreno, Christophe Hezode, Patrick Marcellin, et al.
Annals of the Rheumatic Diseases|November 15, 2015
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC studyDavid Saadoun, Vincent Thibault, Si Nafa Si Ahmed, et al.
Journal of Hepatology|December 10, 2017
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studiesChristophe Hezode, Nancy Reau, Evguenia S Svarovskaia, et al.
Pageof 4